DAY 101-001, A Phase 2 Study of the Oral pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Mutated Low Grade Glioma
Clinical Trial Grant
Awarded By
DOT Therapeutics-1
Start Date
April 26, 2021
End Date
April 30, 2026
Awarded By
DOT Therapeutics-1
Start Date
April 26, 2021
End Date
April 30, 2026